Clinical Guidelines and Quality Measures

Cologuard is included in these prominent clinical guidelines and quality measures:

Healthcare Effectiveness Data and Information Set (HEDIS)

Cologuard is included in the Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colon cancer screening. The NCQA recommended that Cologuard be added to the 2017 HEDIS quality measures and initiated the inclusion.

The NCQA includes Cologuard with its HEDIS measures with 3 years of credit. Specifically, quality credit can be earned for all eligible patients screened with Cologuard this year.

US Preventive Services Task Force (USPSTF)

Cologuard is included in the US Preventive Services Task Force (USPSTF) guidelines on colon cancer screening as of its June 2016 update.

The USPSTF strongly recommends colon cancer screening for people aged 50-75 (‘A’ rating), meaning the committee finds a substantial net benefit in colon cancer screening.

Cologuard is included in the guidelines as a screening option with a three-year interval on equal standing among the other colon cancer screening options, including colonoscopy, CT colonography, flexible sigmoidoscopy, flexible sigmoidoscopy with FIT, gFOBT, and FIT.

Read the full USPSTF guidance as published in JAMA »

American Cancer Society (ACS)

Cologuard is included in American Cancer Society's Colorectal Cancer Prevention and Early Detection Guidelines. The guidelines include Cologuard in a recommended list of screening options.

ACS guidelines also reflect the Centers for Medicare and Medicaid Services assessment that Cologuard be performed every three years for patients 50 and older who do not have symptoms of colorectal cancer and who do not have an increased risk of colorectal cancer. Medicare covers Cologuard for individuals age 50-85 fitting these criteria once every three years at no cost to patients.